Drug Companies Could Look to Tobacco Industry for Solutions as Opioid Crisis Lawsuits Mount

Pharmaceutical giant Johnson & Johnson was ordered to pay $572 million to Oklahoma for its role in the state’s opioid epidemic. While there are certainly more suits and settlements to come, companies’ aversion to financial accountability may result in the American public seeing a repeat of the tobacco industry's addiction-related accord in the late 1990s.

On Monday, Cleveland County District Judge Thad Balkman declared that "the opioid crisis has ravaged the state of Oklahoma” and ruled that Johnson & Johnson should pay $572 million for its role in fueling the epidemic. Though the pharmaceutical giant was not ordered to pay the $17 billion the Oklahoma attorney general was seeking, the company maintains that its business practices were ethical, according to a statement published after the verdict. Johnson and Johnson is expected to appeal Balkman’s decision in the state’s supreme court.

NBC reported Tuesday that drugmaker Purdue Pharma was in months-long talks with local and state government lawyers to settle roughly 2,000 lawsuits concerning its role in supplying opioids - a deal that would see it declare bankruptcy and pay out as much as $12 billion.

Dr. Louis Kyriakoudes, a professor at Middle Tennessee State University and director of the Albert Gore Research Center, joined Radio Sputnik’s Loud and Clear on Tuesday to discuss the ruling and draw comparisons between the opioid epidemic settlements versus those of the late ‘90s involving tobacco.

According to “A State-by-State Look at the 1998 Tobacco Settlement 20 Years Later” by the Campaign for Tobacco-Free Kids, states reaped $27.5 billion from the MSA and tobacco taxes in Fiscal Year 2018, but spent less than 3% of it on programs to stop children from picking up the habit or helping chronic smokers quit.

source